Chao Zhou1, Wentao Li2, Jinchen Shao3, Jikai Zhao3. 1. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China. 2. Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China. Liwentootoo@163.com. 3. Department of Pathology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China.
Abstract
BACKGROUND: Thoracic solitary fibrous tumors (TSFTs) are uncommon mesenchymal tumors. The data regarding surgical outcomes and prognostic factors are scarce. This retrospective paper is to analyze surgical outcomes, clinical characteristics and prognosis of TSFT. METHODS: A single-center retrospective study of the data of 70 patients with TSFT who underwent surgical resection in our department between August 2008 and October 2014 was conducted. RESULTS: A total of 70 TSFTs (58 benign, 12 malignant) were included and all patients underwent complete surgical resection except one recurrent patient with initial treatment. TSFTs originated from the pleura (n = 43), lung (n = 9), mediastinum (n = 16), esophagus (n = 1) and diaphragm (n = 1), respectively. Mass excision was only performed in 29 patients, en bloc excision including surrounding structures was performed in 41 patients. During follow-up, no tumor recurrence occurred in benign TSFT patients. All recurrences occurred in 6 malignant patients, and 5 of them died because of local recurrence and distant metastasis. Median follow-up was 95 months (range, 3-133 months). The 5-year overall survival (OS) of TSFT patients was 94.3%. The 5-year relapse-free survival and OS of malignant TSFT patients were 58.3% and 66.7%, respectively. CONCLUSION: The gold standard of TSFT treatment is complete surgical resection. VATS is safe and reliable for treating selected TSFT patients. Aggressive surgical resection could be underwent in such patients of local recurrence or solitary metastatic tumor. A long-term follow-up is necessary due to the risk of recurrence.
BACKGROUND:Thoracic solitary fibrous tumors (TSFTs) are uncommon mesenchymal tumors. The data regarding surgical outcomes and prognostic factors are scarce. This retrospective paper is to analyze surgical outcomes, clinical characteristics and prognosis of TSFT. METHODS: A single-center retrospective study of the data of 70 patients with TSFT who underwent surgical resection in our department between August 2008 and October 2014 was conducted. RESULTS: A total of 70 TSFTs (58 benign, 12 malignant) were included and all patients underwent complete surgical resection except one recurrent patient with initial treatment. TSFTs originated from the pleura (n = 43), lung (n = 9), mediastinum (n = 16), esophagus (n = 1) and diaphragm (n = 1), respectively. Mass excision was only performed in 29 patients, en bloc excision including surrounding structures was performed in 41 patients. During follow-up, no tumor recurrence occurred in benign TSFT patients. All recurrences occurred in 6 malignant patients, and 5 of them died because of local recurrence and distant metastasis. Median follow-up was 95 months (range, 3-133 months). The 5-year overall survival (OS) of TSFT patients was 94.3%. The 5-year relapse-free survival and OS of malignant TSFT patients were 58.3% and 66.7%, respectively. CONCLUSION: The gold standard of TSFT treatment is complete surgical resection. VATS is safe and reliable for treating selected TSFT patients. Aggressive surgical resection could be underwent in such patients of local recurrence or solitary metastatic tumor. A long-term follow-up is necessary due to the risk of recurrence.
Authors: Winan J van Houdt; Charlotte M A Westerveld; Joyce E P Vrijenhoek; Joost van Gorp; Frits van Coevorden; Cornelis Verhoef; Thijs van Dalen Journal: Ann Surg Oncol Date: 2013-09-20 Impact factor: 5.344
Authors: Javier Martin-Broto; Silvia Stacchiotti; Antonio Lopez-Pousa; Andres Redondo; Daniel Bernabeu; Enrique de Alava; Paolo G Casali; Antoine Italiano; Antonio Gutierrez; David S Moura; Maria Peña-Chilet; Juan Diaz-Martin; Michele Biscuola; Miguel Taron; Paola Collini; Dominique Ranchere-Vince; Xavier Garcia Del Muro; Giovanni Grignani; Sarah Dumont; Javier Martinez-Trufero; Emanuela Palmerini; Nadia Hindi; Ana Sebio; Joaquin Dopazo; Angelo Paolo Dei Tos; Axel LeCesne; Jean-Yves Blay; Josefina Cruz Journal: Lancet Oncol Date: 2018-12-18 Impact factor: 41.316
Authors: A Gupta; C A Souza; H S Sekhon; M M Gomes; S S Hare; P P Agarwal; J P Kanne; J M Seely Journal: Clin Radiol Date: 2017-05-08 Impact factor: 2.350
Authors: Pier Luigi Filosso; Sofia Asioli; Enrico Ruffini; Paolo Rovea; Luigia Macri'; Anna Sapino; Sergio Bretti; Paraskevas Lyberis; Alberto Oliaro Journal: Lung Cancer Date: 2008-11-28 Impact factor: 5.705
Authors: Karen M Harrison-Phipps; Francis C Nichols; Cathy D Schleck; Claude Deschamps; Stephen D Cassivi; Paul H Schipper; Mark S Allen; Dennis A Wigle; Peter C Pairolero Journal: J Thorac Cardiovasc Surg Date: 2009-07 Impact factor: 5.209
Authors: Giuseppe Cardillo; Luigi Carbone; Francesco Carleo; Nicola Masala; Paolo Graziano; Antonio Bray; Massimo Martelli Journal: Ann Thorac Surg Date: 2009-11 Impact factor: 4.330